Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care in the Westminster Hall debate on Parkinson's disease on 17 November 2025, col. 230WH, what steps he will take to encourage medical researchers to propose more projects for National Institute for Health and Care Research funding to help cure that disease.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the 2024/25 financial year, the NIHR committed £6 million to Parkinson’s disease research through its research programmes and capacity building schemes.

As well as funding research itself, the NIHR invests significantly in research expertise and capacity, specialist facilities, support services, and collaborations to support and deliver research in England. Collectively this forms NIHR infrastructure. NIHR infrastructure enables the country’s leading experts to develop and deliver high-quality translational, clinical, and applied research into Parkinson’s disease.

In order to inform priorities and guide future research commissioning by funders of Parkinson’s research, the NIHR Dementia and Neurodegeneration Policy Research Unit at Exeter has undertaken a mapping exercise of the current evidence landscape.

The NIHR continues to welcome funding applications for research into any aspect of human health and care, including Parkinson’s disease. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

Welcoming applications on Parkinson's disease to all NIHR programmes enables maximum flexibility both in terms of amount of research funding a particular area can be awarded, and the type of research which can be funded.

Question to the Cabinet Office:

To ask the Minister for the Cabinet Office, whether the National Security Adviser (a) has briefed and (b) will brief the Intelligence and Security Committee on the sensitive security implications of the proposed new Chinese super-embassy in London.

Answered by Dan Jarvis - Minister of State (Cabinet Office)

The Government and the National Security Adviser maintain a regular and constructive dialogue with the Intelligence and Security Committee of Parliament (ISC) across the full range of national security and intelligence matters

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he has taken with the Secretary of State for Defence to ensure that NHS practitioners are informed of the vulnerability to suicidal ideation of veterans impacted by Lariam; and what steps veterans can take with his Department to help improve awareness within the NHS of the nature and effects of mefloquine toxicity.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its safety advice on mefloquine to reflect the risk of neuropsychiatric side effects, advising that it should not be used for chemoprophylaxis in individuals with a history of psychiatric disturbance.

National Institute for Health and Care Excellence guidance states that mefloquine should not be prescribed to people with current or past psychiatric disorders, suicidal ideation or behaviour, or with epilepsy or any form of convulsion.

The clinical management of suspected mefloquine intoxication has recently been reviewed with the NHS England Armed Forces Clinical Reference Group. This review advised that clinicians should assess patients individually and are expected to take a full drug and alcohol history, including any previous mefloquine use.

NHS England is considering adding screening for prior mefloquine use and any associated adverse events to initial Op COURAGE and Op RESTORE assessments. Additional clinical guidance on mefloquine and its potential adverse effects is being developed and through the Five Eyes partnership discussions are being arranged with the United States to support continuous learning and best practice in the management of suspected mefloquine intoxication.

Harm caused by exposure to sodium valproate

Legacy of British troops in Afghanistan and Iraq